Deutsche Municipal Income Trust (KTF) Forms $11.04 Double Bottom; Agios Pharmaceuticals (AGIO) Shorts Raised By 5.46%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Logo

Agios Pharmaceuticals Inc (NASDAQ:AGIO) had an increase of 5.46% in short interest. AGIO’s SI was 5.59M shares in April as released by FINRA. Its up 5.46% from 5.30M shares previously. With 400,600 avg volume, 14 days are for Agios Pharmaceuticals Inc (NASDAQ:AGIO)’s short sellers to cover AGIO’s short positions. The SI to Agios Pharmaceuticals Inc’s float is 13.01%. The stock decreased 1.98% or $1.71 during the last trading session, reaching $84.74. About 70,304 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 41.40% since April 23, 2017 and is uptrending. It has outperformed by 29.85% the S&P500.

Deutsche Municipal Income Trust (KTF) formed double bottom with $10.26 target or 7.00% below today’s $11.04 share price. Deutsche Municipal Income Trust (KTF) has $431.90M valuation. The stock decreased 0.32% or $0.035 during the last trading session, reaching $11.035. About 28,237 shares traded. Deutsche Municipal Income Trust (NYSE:KTF) has declined 15.48% since April 23, 2017 and is downtrending. It has underperformed by 27.03% the S&P500.

Since January 10, 2018, it had 1 buying transaction, and 20 sales for $17.04 million activity. Bowden Christopher also sold $164,661 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares. 13,000 shares were sold by Schenkein David P, worth $1.05M on Thursday, March 1. The insider Biller Scott sold 3,000 shares worth $228,128. $161,250 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was sold by Alenson Carman on Friday, January 12. Hoerter Steven L. had sold 2,050 shares worth $161,192 on Thursday, February 22. On Monday, March 19 Foster-Cheek Kaye I sold $557,396 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) or 6,800 shares. $16,688 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares were bought by Scadden David.

Investors sentiment increased to 1.22 in 2017 Q4. Its up 0.01, from 1.21 in 2017Q3. It improved, as 19 investors sold Agios Pharmaceuticals, Inc. shares while 48 reduced holdings. 27 funds opened positions while 55 raised stakes. 45.70 million shares or 2.27% more from 44.69 million shares in 2017Q3 were reported. Hbk Limited Partnership holds 0% or 5,355 shares in its portfolio. Spark Investment Mgmt Ltd has invested 0.04% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Whittier Of Nevada stated it has 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Ameriprise Fin stated it has 54,487 shares or 0% of all its holdings. Royal State Bank Of Canada owns 314,261 shares for 0.01% of their portfolio. Tower Research Lc (Trc) has 68 shares for 0% of their portfolio. Us Comml Bank De reported 113 shares. Jennison Limited Com, a New York-based fund reported 166,255 shares. Pnc Financial Serv Grp Inc Inc reported 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Brown Advisory Incorporated holds 0.06% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 304,525 shares. Wells Fargo Company Mn owns 71,065 shares. Tiaa Cref Investment Mngmt Limited Com invested in 0% or 108,369 shares. Moreover, Jabre Cap Sa has 0.4% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 34,000 shares. Parametric Port Assoc Limited Liability Corp has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Axa holds 173,137 shares or 0.04% of its portfolio.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.86 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 45 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Buy” rating given on Monday, October 24 by Needham. Credit Suisse maintained it with “Outperform” rating and $95 target in Wednesday, April 11 report. Canaccord Genuity maintained it with “Buy” rating and $9000 target in Monday, June 5 report. SunTrust maintained the shares of AGIO in report on Tuesday, October 3 with “Buy” rating. Oppenheimer maintained the stock with “Buy” rating in Monday, June 26 report. BTIG Research initiated the stock with “Neutral” rating in Friday, August 19 report. The stock has “Overweight” rating by JP Morgan on Monday, June 13. Credit Suisse maintained it with “Buy” rating and $80.0 target in Thursday, February 15 report. The stock has “Buy” rating by RBC Capital Markets on Wednesday, November 1. As per Wednesday, February 14, the company rating was maintained by RBC Capital Markets.

Investors sentiment increased to 1.4 in 2017 Q4. Its up 0.19, from 1.21 in 2017Q3. It is positive, as 5 investors sold Deutsche Municipal Income Trust shares while 15 reduced holdings. 16 funds opened positions while 12 raised stakes. 3.58 million shares or 44.35% more from 2.48 million shares in 2017Q3 were reported. West Virginia-based Security Natl Trust Com has invested 0% in Deutsche Municipal Income Trust (NYSE:KTF). Weiss Asset Management Limited Partnership owns 14,927 shares for 0.02% of their portfolio. Millennium Mgmt Limited Liability invested in 0% or 16,604 shares. First Allied Advisory Serv, a Missouri-based fund reported 20,551 shares. Lpl Fincl Limited Liability stated it has 0% in Deutsche Municipal Income Trust (NYSE:KTF). Sg Americas Secs Ltd Liability Corporation owns 38,981 shares for 0% of their portfolio. Robinson Ltd Liability Co holds 1.71% or 299,192 shares. 23,396 are held by Raymond James Fincl Svcs Advisors Incorporated. Morgan Stanley, a New York-based fund reported 111,222 shares. Mackay Shields Limited Liability Company reported 0.05% of its portfolio in Deutsche Municipal Income Trust (NYSE:KTF). Wolverine Asset Mngmt Limited Liability Corp holds 0.01% or 103,709 shares in its portfolio. Raymond James And Assoc accumulated 23,584 shares or 0% of the stock. Northern Trust Corporation stated it has 23,110 shares. Pnc Financial Grp stated it has 10,600 shares or 0% of all its holdings. Sit Assoc Inc has 121,465 shares.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart